Biotricity, Inc. to Attend 34th Annual Roth Conference March 13th-15th
Biotricity, Inc. (NASDAQ:BTCY) announced its participation in the 34th Annual Roth Conference from March 13-15, 2022, in Dana Point, California. This follows a strong fiscal third quarter, reporting a 93% year-over-year revenue growth and its highest cash position. The company is now taking preorders for Biotres, a new FDA-cleared wireless cardiac monitoring device aimed at the $5.7 billion market for cardiac arrhythmia monitoring. The device enhances long-term ECG data collection, expected to ship starting April 1, 2022.
- None.
- None.
- Follows fiscal third quarter earnings that saw revenue up
93% year-over-year and Company's highest-ever quarterly cash position - Biotricity now taking preorders for Biotres, an FDA-cleared, wireless, wearable cardiac arrhythmia monitoring device
REDWOOD CITY, CA / ACCESSWIRE / March 4, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that it will attend the 34th Annual Roth Conference, being held on March 13-15, 2022 at The Ritz Carlton, Laguna Niguel in Dana Point, California.
The conference is one of the largest in the nation for small-cap companies. This year, the event will consist of 1-on-1 meetings and select analyst fireside chats. You can follow Biotricity's Roth webcast at https://wsw.com/webcast/roth43/btcy/1832776.
"Our appearance at the 34th Annual Roth Conference comes at a very exciting and pivotal time for Biotricity," said Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO. "Following our recent fiscal third quarter results reflecting a
Biotres is a three-lead device designed to continuously record electrocardiogram (ECG) data for long term data collection. This wireless, wearable device aims to provide doctors and hospitals a secondary product option to meet their patients' cardiac monitoring needs. This product can potentially offer doctors a more cost-effective alternative to current devices, along with a faster diagnosis. Following the FDA's clearance of Biotres last month, Biotricity, on February 23, 2022, officially announced that it began taking preorders. Units plan to start shipping on April 1, 2022.
The Biotres announcement follows last quarter's launch of Bioheart, a groundbreaking step towards the Company's ultimate goal of building a complete cardiac ecosystem. Bioheart is a cardiac monitor that took less than a year to come to market. The device offers patients the same continuous heart monitoring technology used by physicians from their own homes.
About the 34th Annual Roth Conference:
Hosted by Roth Capital Partners, LLC, a full-service investment bank providing services to emerging growth companies and investors, the 34th Annual Roth Conference is scheduled for March 13-15, 2022, at The Ritz Carlton, Laguna Niguel, in Dana Point, California. Events. The conference will have companies across broad sectors, including consumer, energy, healthcare, industrial growth, metals & mining, sustainability, services, technology, and more.
5100+ attendees, 500+ attending companies, and 100+ sponsors are expected to attend.
To register, please contact a Roth Sales Representative at 800.678.9147 or submit a request to https://www.meetmax.com/sched/event_75329/conference_register.html
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic products for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit: www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts:
Investor Relations:
Biotricity Inc.
1-800-590-4155
investors@biotricity.com
SOURCE: Biotricity, Inc.
View source version on accesswire.com:
https://www.accesswire.com/691525/Biotricity-Inc-to-Attend-34th-Annual-Roth-Conference-March-13th-15th
FAQ
What were Biotricity's latest financial results?
When is Biotricity attending the Roth Conference?
What is Biotres and when will it be available?
How does Biotres aim to impact the cardiac monitoring market?
What type of events will occur at the Roth Conference?
